The Grand Rapids Clinical Oncology Program (GRCOP) has achieved a national reputation for excellence in community cancer care through its 34-year participation in programs of the National Cancer Institute. The GRCOP comprises a consortium of seven health care systems/hospitals in Western and Northern Lower Michigan and seeks to continue to meet the community's need for innovative and relevant studies of promising therapeutic modalities and cancer controls research. The ongoing mission of the Grand Rapids Clinical Oncology Program is to assure that every person in the region served is provided an opportunity for participation in national cancer prevention and treatment clinical trials. Additionally, it is a major educational resource for professional and laypersons alike regarding cancer and the NCI clinical trials program. This grant application encompasses and articulates an ever-expanding vision for the GRCOP. Key strategies to increase patient access and accrual to research protocols include: (1) expansion of on-site screening and patient identification for enrollment in research protocols;(2) strengthening referral systems for symptom management trials to include physician specialists and allied health professionals;(3) maintaining a protocol menu that is comprehensive yet efficient to administer;(4) expansion of the Radiation Therapy Oncology Group (RTOG) as a research base for all component sites;(5) implementing a targeted clinical trials program for adolescents/young adults with increased protocol availability for this population. Strategic initiatives to increase access to and participation in cancer clinical trials by underserved and minority populations include alignment with community organizations;a key element in this regard will be the work of the GRCOP Patient Advisory Board. An expanding focus on the growing Hispanic/Latino population is planned. Of importance during this upcoming grant cycle will be the GRCOP's ongoing development of the GRCOP website in order to improve the efficiency and cost-effectiveness of clinical trial administration and regulatory compliance.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
3U10CA035178-30S1
Application #
8854484
Study Section
Special Emphasis Panel (ZCA1-SRLB-Y (J1))
Program Officer
Whitman, Cynthia B
Project Start
1987-06-01
Project End
2014-07-31
Budget Start
2013-06-01
Budget End
2014-07-31
Support Year
30
Fiscal Year
2014
Total Cost
$219,652
Indirect Cost
$63,289
Name
Spectrum Health Hospitals
Department
Type
DUNS #
047593173
City
Grand Rapids
State
MI
Country
United States
Zip Code
49503
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O⁶-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Persky, Daniel O; Miller, Thomas P; Unger, Joseph M et al. (2015) Ibritumomab consolidation after 3 cycles of CHOP plus radiotherapy in high-risk limited-stage aggressive B-cell lymphoma: SWOG S0313. Blood 125:236-41
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Ramanathan, Ramesh K; McDonough, Shannon L; Kennecke, Hagen F et al. (2015) Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer 121:2193-7
Yu, Evan Y; Li, Hongli; Higano, Celestia S et al. (2015) SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 33:1601-8
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-40
Allen, Jeffrey W; Moon, James; Redman, Mary et al. (2014) Southwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer. J Clin Oncol 32:2463-70
Gralow, Julie R; Barlow, William E; Lew, Danika et al. (2014) A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102. Breast Cancer Res Treat 143:351-8

Showing the most recent 10 out of 173 publications